CHRS Coherus BioSciences, Inc.

27.15
+0  (0%)
Previous Close 27.15
Open 27.05
Price To book 36.06
Market Cap 1.19B
Shares 43,652,000
Volume 268,727
Short Ratio 14.95
Av. Daily Volume 374,124

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due 1H 2017.
CHS-1420
Psoriasis
PDUFA date June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. Coherus Offers Positive Phase III Data on Humira Biosimilar
  2. Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
  3. Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : January 10, 2017
  4. Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
  5. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 19, 2016
  6. Coherus BioSciences to Present at BMO – Prescriptions for Success Healthcare Conference on December 14th
  7. Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : December 7, 2016
  8. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 6, 2016
  9. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  10. Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted
  11. Is The Rubicon Project Inc (RUBI) A Good Stock To Buy?
  12. Coherus BioSciences Announces New Employment Inducement Grants
  13. Coherus BioSciences Announces New Employment Inducement Grants
  14. COHERUS BIOSCIENCES, INC. Financials
  15. Edited Transcript of CHRS earnings conference call or presentation 9-Nov-16 9:30pm GMT
  16. Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today
  17. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  18. Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results
  19. Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results
  20. AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS)